Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Samyang Corporation
The UK-headquartered life sciences investment firm has comfortably exceeded its target of $350m for a fund dedicated to taking on late-stage products, incurring all the clinical and regulatory risk and receiving a pre-negotiated return once the drug is approved.
Public Company Edition: Merging with a special purpose acquisition corporation may be an attractive alternative to an initial public offering, but February’s vigorous IPO pace includes seven recent offerings that raised $480.8m in the US. Also, Cassava raised $200m and KalVista brought in $222.5m.
The ABV 8 fund will invest $15m to $30m per company across the range from start-ups to development-stage companies.
Public Company Edition: The new year started with two companies signaling plans for significant near-term initial public offerings, following Inhibikase’s launch as the last IPO of 2020. Other recent financial highlights include layoffs at Calithera and Regenxbio’s $200m Zolgensma royalty sale.
- Contract Manufacturing Organization
- Other Names / Subsidiaries
- Samyang Pharmaceuticals Corp.
- Samyang Biopharm USA, Inc.